( TM) treated group of patients, the mean HbA1c level was reduced by 0.94% to 1.21% vs. baseline levels in months 2 to 6 post-treatment.
The mean HbA1c levels of the placebo group ranged from a reduction of 0.1% to an increase of 1.0% over the same period.